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Viral myocarditis is described as the inflammation of the heart muscle, and it is a common 
condition that can affect the heart. It is estimated that myocarditis causes 1.5 million deaths 
annually. In mice, Theiler’s encephalomyelitis virus (TMEV) is a common cause of myocarditis. 
This non-attenuated virus can be used in a cell culture model system to study viral replication and 
persistence. These processes have been linked to the severity of the heart damage, which in most 
clinical scenarios, can lead to dilated cardiomyopathy. The 5’ untranslated region (5‘UTR) found 
in the viral genome of TMEV is well known to control viral replication. In particular, the internal 
ribosome entry site (IRES) elements of the 5'UTRs are involved in the replication and translation 
regulation. In patients suffering from chronic myocarditis, the IRES has been found to acquire 
deletions, suggesting a strong correlation between mutations, viral persistence and pathogenicity. 
Similarly, deletions in the 5’UTR secondary loop regions have been linked to increased viral 
infections. The goal of the research project is to study the 5’UTR region of TMEV to understand 
its role in viral replication and persistence. During the course of this research project, I designed a 
cloning strategy to generate four recombinant deletion viruses to test their ability to infect primary 
cardiac cells. The designed deletions maintained the secondary RNA structures loop, which is 
important for the recognition of the virus by the host’s immune system.  In summary, this research 
will help to better understand the role of 5’UTR elements in regulation of viral replication and its 
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Human heart disease is the number one killer worldwide, and it is accounted for 17.3 
million deaths annually 1. Heart disease refers to several conditions that can affect the heart, 
including, but not limited to, coronary artery disease, heart failure, myocarditis, and others. 
Myocarditis is a heart condition that accounts 1.5 million deaths of the total heart disease 
conditions globally 2. The incidence of myocarditis is estimated to be between 10 to 20 per 100.000 
people worldwide 3. Although myocarditis can be caused by several infectious agents (bacteria, 
fungi, parasites), it is most commonly triggered by viral infections 4,5.  
Viral Myocarditis  
Viral myocarditis is an inflammation of the heart muscle (myocardium) that can lead to 
dilated cardiomyopathy 6. It can be characterized by a profound infiltration of immune cells as a 
result of viral infection of the heart 6,7. Thus, it has been hypothesized to have an autoimmune 
pathogenesis 8. The aspects responsible for the initiation and continuation of the immune response 
are still unclear, but the involvement of infectious agents have been suggested.  
Picornaviruses are common etiologic agents for myocarditis 8,9. Recent studies have shown 
that a viral infection of cardiomyocytes is required for the development of myocarditis and 
subsequent cardiomyopathy 6,10. Viral infections can cause significant damage to cardiomyocytes 
through direct injury and secondary immune reactions, leading to acute and subacute phases of 
myocarditis 11,12. Of special interest is the observation that 35%-50% of patients with myocarditis 
developed a persistent enteroviruses infection of the heart, which is associated with the heart 
damage in the chronic phase of the disease, leading to dilated cardiomyopathy 3. This demonstrates 
that the viral infection of cardiomyocytes is an important step that determines the pathogenesis 
and persistence of the virus during a systemic infection. Coxsackievirus group B3 (CVB3) is a 
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good example of enterovirus-induced myocarditis in humans and it is detected in 20%-30% of all 
viral myocarditis related cases 13. The isolation of CVB3 RNA genome from a heart tissue taken 
from patient with DCM showed deletions of 15 to 48 nucleotides in the 5’ untranslated region 
(5’UTR) of the viral genome, suggesting a strong association between deletions within the 5’UTR 
and viral virulence 14. Those deletions were characterized by a low viral RNA load (8.10 
(2)copies/μg of nucleic acids), leading to viral persistence and  DCM 14. It is well-documented that 
the 5’UTR regulates viral replication, so deletions within this particular region were presumed to 
be associated with chronic myocarditis 14,15. Moreover, many picornaviruses are known to cause 
myocarditis, with similar mechanisms and complications in humans, in experimentally inoculated 
mice, as shown in Theiler’s Murine Encephalomyelitis Virus (TMEV) model system13,16,17. 
TMEV is a non-enveloped positive single-stranded RNA virus belonging to the 
Cardioviruses genus of Picornaviruses. It is  a natural pathogen in mice that can cause myocarditis 
through direct damage to cardiomyocytes, which is similar to human cases of myocarditis 17,18. 
Omura s. et al. have revealed cardiomyocyte damage in TMEV-infected mice groups that was 
characterized by high troponin I levels and high viral RNA loads at 4 days post-infection (r=0.79; 
P<0.05) 18. In addition to the similar mechanisms of disease initiation, DA strain of TMEV was 
proven to induce triphasic myocarditis, and to imitate clinical and immunological findings in 
human CVB3-induced myocarditis17,18. The DA strain sequence was found to be more closely 
related to members of the Cardiovirus genus than to members of other Picornavirus genera 19. The 
intraperitoneal infection of C3H mice with TMEV (DA strain) lead to an infection of the heart and 
the development of the three phases: acute, subacute, and chronic 20. The acute phase was 
characterized by viral pathology inducing innate immune response, and the subacute phase was 
characterized by the antiviral immune responses and autoimmunity that lead to more damage of 
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the myocardium20. As a result of heart damage during the acute and subacute phases, cardiac 
remodeling was revealed as a dominant event of chronic phase 20. Moreover, susceptibilities to 
TMEV-induced myocarditis were shown to differ among mouse strains.  The most highly 
susceptible strain was the C3H strain and the intermediate susceptible strain was the C57BL/6. 
However, a highly resistant strain was the SJL/J 18,20. It was demonstrated that TMEV-infected 
C3H mice developed all three phases, while SJL/J mice developed only the acute phase and 
C57BL/6 mice developed both acute and subacute phases 18,20. The different susceptibilities to 
viral myocarditis were dependent on the genetic background of each mouse strain, and that has 
also been demonstrated in humans 21. With information given, it can be said that several aspects of 
TMEV-induced myocarditis have been reported in scientific literature allowing the establishment 
of TMEV as a model system to study myocarditis in 2014 18,17. Those aspects focused on showing 
the similarities between TMEV and its homologs in humans in regards to myocarditis molecular 
mechanisms, immunological and clinical findings, and host suitability, shedding the light on using 
TMEV as a model system to further understand human viral myocarditis. Most importantly, 
TMEV translation and replication was shown to be controlled by the 5’UTR as in most 
Picornaviruses 22. However, the role of genetic regions of TMEV genome in viral infection or 
persistence in myocarditis in mice was not given much attention.  
The TMEV genome is 8093 nucleotides long with a poly(A) tail and it has a 5' UTR that 
stretches from nucleotides 1 to 1065. The 5’ UTR contains highly structured stem-loops that were 
shown to be conserved throughout Cardioviruses (Figure 1) 23. This suggests the importance of 
these loops in regulating viral replication within the cardiomyocytes during heart infection, which 
possibly leads to viral persistence in the heart. Therefore, studying the 5’UTR region of TMEV 
might help identify important regions that can mediate viral infection and the likelihood to cause 
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damage in primary cardiac cell lines. Also, manipulating the TMEV genome by introducing 
deletions in the 5’ UTR region might help to determine the effect of these deletions on viral 
persistence by measuring the immune response of viral mutant TMEV-infected cardiac cell lines. 
Most importantly, using TMEV to investigate the role of genetic regions in the 5’UTR will further 
our understanding of human myocarditis by defining similar regions in the CVB3 genome. 
Material and Methods  
Plasmids  
TMEV cDNA 
The full TMEV sequence was cloned into a full-length pDAFI3 cDNA vector, which was 
kindly obtained from Dr. Rymond P. Roos’ lab from the University of Chicago. The pDAFI3 
plasmid contained a T7 promoter, recognition sites for XhoI, ClaI, and Xbal restriction enzymes, 
Amplification region, and the viral cDNA downstream of the T7 promoter (Figure 2). 
Deletion construct  
The desired deletion sequence in the 5’UTR region of TMEV was cloned into pUC75 
plasmid, and was ordered from BioBasic company.   
Cell lines  
BHK-21 Cell lines 
 The Baby Hamster Kidney (BHK-21) cell line was kindly provided by Dr. John Rose 
(Yale University, New Haven, Connecticut). The BHK-21 were maintained in Dulbecco modified 
Eagle medium (DMEM) containing 10% Calf serum (iron supplemented) + 1% 
glutamine/penicillin/streptomycin. The cells were passaged every 48 hours according to standard 
cell culture passing protocol. 
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MCM cell lines  
The Mouse Cardiac Myocyte (MCM) C57BL/6 (primary cardiac cell line for TMEV viral 
infection) were ordered from ScienCell Research Laboratories. The MCM cell lines were 
maintained in Mouse Cardiac Medium-serum free media (ordered from ScienCell Research 
Laboratories). The cells were passaged every 72 hours according to the standard cell culture 
passing protocol. 
Cell culture passaging protocol 
 All cell cultures were maintained at 37°C and in 5% CO2 incubator. Briefly, cells were 
washed with 3mL PBS (2x). Then, 0.5mL Trypsin was added, and flasks were incubated at 37°C 
for 2 minutes to detach the cells. 4ml of DMEM media was added and cell suspension was  
transferred into a 15ml falcon tube and centrifuged for 5 minutes at speed of 4400 rcf. Then, media 
was removed without disrupting the pellet and 5mL of fresh media was added. The cells were 
counted by adding 10µl of cell suspension and 10µl TrypanBlue in a new Eppendorf tube. The 
cells were plated (based on calculations) in new T-25 flasks. 
Generation of mutant TMEV 
Primer design  
Primers were designed to flank deletions in the 5’UTR region that varied in size to generate 
four different recombinant TMEVs (Figure 3A). The first deletion construct was designed to flank 
the desired sequence of 20 nucleotides. The subsequent constructs contained deletions of 40 





mFOLD program  
mFOLD program was used to create the deletions in the 5’ UTR region of the TMEV. The 
program allows to estimate the formation of the secondary RNA structure and the confirmation of 
preserving the single loop structure of loop A in the 5’UTR.  
Bacterial Transformation 
 Bacterial transformation was carried out to amplify pDAFI3 and pUC75 plasmids. Briefly, 
1µl of plasmid was added to 50µl of E.coli competent cells and placed on ice for 30 minutes. Then, 
the E.coli competent cells were heat-shocked at 42qC for 30 seconds and placed back into ice for 
1 minute. 300 µl of Super Optimal Broth (S.O.C) was added to obtain maximal transformation 
efficiency of E. coli. The tubes were incubated on a shaking platform of a 37qC incubator for 1 
hour.  100µl of mixtures were plated onto LB agar plates with ampicillin (100 µg/mL) and the 
plates were incubated for 24 hours at 37°C.  
The next day, the transformed bacterial colonies were grown in liquid cultures of 2mL LB 
broth and 2 µl of 1000x ampicillin stock (100 mg/ml). The bacterial growth tubes were incubated 
on a shaking platform of a 37°C incubator for 24 hours.  
DNA isolation protocol 
The plasmids were purified using a phenol:chloroform:IAA extraction (SigmaAldrich). 
Briefly, 1.5 mL of bacterial culture was transferred into a new Eppendorf tube and centrifuged for 
5 minutes at 14,000 rpm. The supernatant was discarded, and the pellet was resuspended in 50μl 
of TE buffer (the buffer contains 10 mM Tris-HCl, pH 8 and 1 mM EDTA),  300μl TENS lysis 
buffer (500ml buffer contains 5 mL 1M Tris-HCl pH 8.0, 12.5 mL 20% SDS, 5 mL 10N NaOH, 
477.5 mL H2O), and 100μl of sodium Acetate (3M NaAc pH 5). The tube was centrifuged for 5 
minutes at top speed 14,000 rpm, and cells were transferred into a new Eppendorf tube. 1μl RNase 
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A was added and tube was incubated at 37°C for 15 minutes. Then, 600μl of 
phenol:chloroform:IAA was added to the mixtures and centrifuged for 10 minutes at 14,000 rpm. 
The upper layer was removed and transferred to new Eppendorf tubes. 200μl of 100% ethanol was 
added and tube was centrifuged for 10 minutes at 14,000 rpm. The supernatant was discarded and 
100μl of 70% ethanol was added and centrifuged for 10 minutes at 14,000 rpm. The supernatant 
was discarded and the pellets were resuspended in 50µl of water. The final concentration was 
measured using Nanodrop. 
Restriction enzyme digestion  
The pDAFI3 and pUC75 plasmids were digested using XhoI and ClaI enzymes  (New England 
Biolabs) by setting up two reactions.  The first reaction was the pDAFI3 reaction and it was 
prepared by adding 5μl of CutSmart buffer, 1μl of ClaI restriction enzyme, 1μl of XhoI restriction 
enzyme, 10μl of DNA, and 33μl of nuclease-free water. The second reaction was the pUC75 
reaction and it was prepared by adding 5μl of CutSmart buffer, 1μl of ClaI restriction enzyme, 1μl 
of XhoI restriction enzyme, 10μl of DNA, and 33μl of nuclease-free water. The reactions were 
incubated at 37°C for 3 hours. 
Dephosphorylation of 5’-end 
Dephosphorylation of 5’-end step was carried out to avoid self-ligation of pDAFI3, using 
quick dephosphorylation kit (M0508) (New England Biolabs). According to the manufacturer’s 
protocol, a reaction of 20 µl was prepared by adding 2µl of CutSmart Buffer (10X), 1 µl of rSAP 
(Shrimp Alkaline Phosphatase) (New England Biolabs), and 18µl of water. The mix reaction was 




Restriction enzyme digestion 
Single digestion was carried out to ensure the efficacy and validity of the restriction enzymes 
(ClaI and XhoI) using only pDAFI3 plasmid. Two reactions were set up: reaction 1 contained 5μl 
of CutSmart Buffer, 1μl of XhoI restriction enzyme, 2μl of TMEV cDNA, and reaction 2 contained 
5μl of CutSmart Buffer, 1μl of ClaI restriction enzyme, 2μl of TMEV cDNA. The two reactions 
were incubated at 37°C for 3 hours.  
Agarose gel electrophoresis  
An agarose gel (0.8%) was prepared to run the digestion reactions from the restriction 
enzyme digestion experiments. To prepare the gel, 0.8 grams of agarose gel powder was mixed 
with 100 ml of TAE buffer and the mixture was heated using microwave for 2 minutes. Then, 
when the solution cooled down, 3µl of SYBR Green Safe dye (Invitrogen) was added.  The gel 
was allowed to solidify in the gel dock for about 20 minutes. To prepare samples, the following 
reactions were mixed: 2µl of cDNA plasmid, 2µl of 6x Loading dye, and 6 µl H2O. The prepared 
samples for the single digestion reactions of pDAFI3 and the double digestion reactions of pDAFI3 
and pUC75 were loaded into the wells, and the gel was run for 40 minutes. The bands were 
visualized using a gel imaging system. The concentrations was measured using a Nanodrop.  
Gel extraction  
The right bands sizes from the double digestion of pDAFI3 and pUC75 were extracted 
from the gel using QlAquick gel extraction kit (50) (Cat. No. 28704 from QIAGEN). According 
to the manufacturer’s protocol, the extracted gel slice was weighted. Then, 300µl of Buffer QG to 
100µl was added to each digestion reaction and placed in water-bath set to 50°C for 10 minutes 
until the gels were completely dissolved. 100µl of isopropanol was added to the reactions and 
reactions were transferred into provided QlAquick spin columns and centrifuged for 1minute. The 
 13 
flow-through was discarded and the QlAquick spin column was placed back into the collection 
tubes. Then, 500µl of Buffer QG was added to the QlAquick spin column and centrifuged for 1 
min. The flow-through was discarded and 700µl of Buffer PE was added and the QlAquick spin 
column and centrifuged for 1 min. The flow-through was discarded and the QlAquick spin columns 
were placed into clean 1.5ml microcentrifuge tubes. The digested cDNA was eluted in 30µl water. 
PCR purification   
The pDAFI3 samples from the single digestion were purified using QIAquick PCR 
Purification Kit (Cat. No.28104) (QIAGEN) according to the manufacturer’s protocol.  
Generation of TMEV RNA 
Restriction Enzyme Digestion  
      The original TMEV cDNA plasmid was linearized by carrying out a single restriction enzyme 
digestion using Xbal restriction enzyme. The digestion reaction was set up by adding 5µl of 
CutSmart Buffer, 2µl of Xbal Restriction Enzyme, 5.7µl of TMEV cDNA and 37.3µl of nuclease-
free water.  
 Agarose gel electrophoresis  
Agarose gel (0.7%) was prepared to run samples from the digestion of the TMEV cDNA. 
The samples were prepared by adding 2µl of TMEV cDNA plasmid, 2µl of 6x Loading dye, and 
6 µl H2O. The control sample was prepared by adding 6µl of wild-type TMEV cDNA plasmid, 
2µl of 6x Loading dye, and 4µl of H2O. The samples were loaded into the gel, and bands were 
visualized using a gel imaging system.  The concentrations was measured using a Nanodrop.  
In-vitro RNA transcription  
In-vitro RNA transcription was carried out to produce an RNA transcript from the 
linearized TMEV cDNA template. pDAFI3 TMEV-cloned vector included T7 promoter that is 
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recognized by T7 RNA polymerase, which was used to reverse transcribe the TMEV cDNA to 
RNA using T7 RiboMAX™ Express Large-Scale RNA Production System kit (Cat No./P1320) 
(Promega). The Reaction was prepared according to the manufacturer’s protocol (Synthesizing 
Large Quantities of RNA protocol) by adding 10 µl of RiboMAX Express buffer, 8µl of linear 
TMV cDNA template, 2 µl of T7 Express Enzyme Mix. The reaction was mixed and incubated at 
37°C for 30 minutes. Then, 1µl of RNase-free DNase was added the in-vitro transcription reaction 
and incubated for 15 minutes at 37qC.  
The linearized TMEV cDNA was purified using a Monarch RNA Cleanup kit (500 µg) 
(Cat.No.T2050S) (New England BioLabs). According to the manufactures’ protocol, 100µl of 
RNA Cleanup Binding Buffer was added to the in-vitro transcription reaction with the linearized 
TMEV cDNA.  150 µl of ethanol (100%) was added and mixed and the sample was loaded onto a 
provided column tube and span down for 1 minute at top speed 14,000 rpm. The flow-through was 
discarded and 500µl RNA Cleanup Wash Buffer was added and span down for 1 minute at top 
speed 14,000 rpm (2x). The column was transferred into RNase-free 1.5 microfuge tube and the 
sample was eluted in 50µl water and incubated at room temperature for 5 minutes and span down 
for 1 minute at top speed 14,000 rpm (2x). The concentration was measured using Nanodrop.  
RNA Electroporation  
TMEV RNA was generated by infecting BHK-21 cells along with repeated passaging, 
following standard viral passaging and electroporation protocols. Briefly, BHK-21 cells were 
resuspended in 4ml  PBS and centrifuged for 5 minutes at top speed. PBS was discarded and the 
cell pellet was resuspended in 1ml PBS (2x). In electroporation Cuvette, 500µl of BHK-21 cells  
was added to 10µl of purified TMEV RNA. The Cuvette was placed into an electroporation 
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machine and pulsed with 300 volts. Finally, the mix was transferred into a prepared T-25 flask 
containing 5ml of fresh iron-supplemented DMEM media and incubated at 37°C overnight.  
 
Results  
1. Derivation of mutant TMEV (RVA20)  
Confirmation of preserved single loop structure of the 5’ UTR region of the TMEV   
The mFOLD program showed that the deletions created in the 5’UTR of TMEV did not 
alter the single loop structure of the loop A in the 5’UTR region.  The mFOLD program showed 
that deletion created in loop A to generate the four recombinant viruses was preserved (Figure 4).  
Restriction enzyme digestion  
Digestion of pDAFI3 plasmid (10.8 kb) was successful and resulted in two bands that 
corresponded to 2 kb (contained the 5’UTR region) and 8.8 kb (contained the remaining sequence 
of TMEV cDNA). The digestion of pUC75 (3.2 kb) plasmid resulted in two bands that 
corresponded to 2 kb (the deletion construct) and 1.2 kb (the remaining sequence of the pUC75 
plasmid).  The single digest products of pDAFI3 cut with XhoI and the pDAFI3 cut with ClaI 
showed a size of 10.8 kb compared to the control of wild-type pDAFI3 plasmid (Figure 5). 
Dephosphorylation of pDAFI3 plasmid 
The pDAFI3 plasmid was dephosphorylated, and no colonies were observed on the LB 
agar plates supplied with ampicillin after bacterial transformation.  
2. Generation of TMEV RNA  
Linearization of pDAFI3 plasmid 
The single digestion of the pDAFI3 plasmid (containing TMEV cDNA) with the Xbal 
restriction enzyme was successful and I was able to visualize a linearized TMEV cDNA product 
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on the agarose gel. The linearized TMEV cDNA was shown as a sharp band of a size 10.8kb, and 
was compared to the band of the control, non-linearized wild-type TMEV cDNA (pDAFI3) 
(Figure 6).  
The effect of TMEV RNA infection of BHK-21 cell lines  
 BHK-21 cells were observed for cytopathic effect to determine the cells death as an 
indication of TMEV RNA growth in those cells. BHK-21 showed a change in morphology where 
they had rounded-shape or they were floating on the surface of the T-25 flask.  In comparison, the 
normal BHK-21 cells showed epithelial morphology and were attached to the surface of the flask, 
indicating no viral infection (Figure 7). 
Discussion  
My research project focuses on studying the conserved loops of the 5’ UTR of the TMEV. 
My goal was to develop a strategy to generate four recombinant TMEV viruses with a 20, 40,60, 
and 84 nucleotides deletions and test these viruses for growth. I was able to design deletions that 
would preserve the secondary loop structure using the mFOLD program. This was important as 
any alterations to secondary RNA structures may impact the viral recognition by the immune 
system. Furthermore, I was able to design a restriction enzyme strategy to replace a 2kb TMEV 
genomic region flanked by XhoI and ClaI restriction enzymes with a viral deletion construct 
(Figure 8).  In the future, this deletion construct will be used to create recombinant viruses and test 
their growth in BHK-21 cell line and a primary cardiac cell line. Consequently, this research will 
reveal the role of 5’UTR of TMEV in viral replication, viral resistance, and pathogenicity.  
The 5’UTR region of viruses is known to be associated with viral replication, translation 
and pathogenicity.  Among Picornaviruses, there is a high degree of sequence conservation in the 
5’UTR region. Furthermore, the 5’UTRs often form secondary structures, such as loops, clover-
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like structures, or pseudoknots. These structures have been implicated in viral replication and 
stability. Interestingly, they may also play a role in the infection cycle of the virus. There are well-
documented examples of viruses with deletions in the 5’ UTR regions that make the virus more 
potent and more likely to infect tissues that are not normally not associated with the primary site 
of infection. For example, loss of nucleotides 1-22 and 1-25 out of the CVB2 cloverleaf increases 
the likelihood of the virus to infect a human heart tissue, and result in myocarditis 24. Furthermore, 
persistent viral populations that belong to the CVB3 virus have been reported to contain up to 48 
deletions in the 5’UTR region of the viral genome. 14  
It is very important to dissect the role of mutations in the 5’UTR region of viral genomes, 
and their impact on viral pathogenicity, as it is related to the function of human heart. It is known 
that the heart can get infected by viruses, and that these viral infections can cause a permanent 
heart damage.  On the other hand, diagnosing heart infections is complicated because of the 
location of the heart. Therefore, studying the function of the 5’UTR of the virus genome can help 
us understand the disease process associated with the viral infection. Particularly, inducing 
deletions in the 5’UTR can offer insight into the processes associated with viral replication, 
translation, and viral potency. 
In future experiments, the described research will be important for assessing why certain 
viral mutations or deletion can have an impact on viral replication and heart function. To facilitate 
these analyses, the BHK-21 cell line will be infected with the mutant TMEV containing the 
induced deletion in the 5’ UTR, and testing for viral growth through the measurement of viral titer 
using a TCID50 method. The other three designed TMEV 5’UTR deletions will also be generated 
in the BHK-21 cell line and tested for growth and the ability to cause infection. All viruses 
generated will be used to produce viral stocks. Briefly, the viruses will be grown in the BHK-21 
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cells for a couple of passages. A titer assay will be performed, and viral pegylation will be used to 
concentrate all viruses. The viruses will be tested in a primary cardiac cell line (Mouse Cardiac 
Myocyte MCM). The same concentration of each virus will be used to infect the primary mouse 
myocyte cells. After CPE is established, the host genetic material (DNA and RNA) will be 
extracted. The host RNA will be reverse transcribed to cDNA, which will be used for quantitative 
PCR assays. Specifically, the regulation of the innate immune system genes will be measured to 
assess the response against each virus. I expect to observe differences in the immune gene 
expression in response to each virus.  
The results obtained in course of these studies will generate a model system to analyze the 
role of the 5’UTR deletions in the TMEV genome in cardiac cell infection. In the future,  the 
knowledge of the 5’UTR important regions might provide better diagnostic tools for patients 
suffering from virus-induced heart disease.  For example, a sequencing analysis might be 
performed on people presenting heart disease symptoms to determine if there are any viruses with 























Figure 1: TMEV RNA viral genome structure. Basic genome structure of TMEV virus. 5’ untranslated 
region (left) with two regions of highly structured stem-loops (IRES and AB region) and capped with Vpg 
protein, 3’ untranslated region (right) with stem-loop structure. Viral proteins (middle) divided into 
structural and non-structural proteins, and involved in structuring and protecting the capsid and regulating 






















Figure 2:. Scheme for construction of plasmid pDAFI3. pDAFI3 vector of TMEV cDNA (10.8kb) with 
the 5’UTR placed downstream the T7 promoter, containing restriction enzyme recognition sites for ClaI 



































































Figure 3: Design of deletions in the 5’UTR of TMEV. A) Deletion design in loop A of the AB region 
(86nt) of the 5’UTR to generate four recombinant TMEV viruses (RV). The four RVs represent deletions 
of 20nt (RVA20), 40nt (RVA40), 60nt (RVA60), and 84nt (RVA84). B) Oligonucleotides Primers of 
TMEV loop A. Primers were designed to induce deletion sequences in loop A of the 5’UTR to generate 
four TMEV recombinant viruses.  
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Figure 4: Secondary RNA structure of 5’UTR. A) Deletion design in the 5’ UTR and B) Images from 


























Figure 5. Digestion of pDAFI3 and pUC75 plasmids.  Restriction enzymes Xbal and ClaI were used to 
digest pDAFI3 and pUC75. Digestion products of pDAFI3 and pUC75 were separated by electrophoresis 
using a 0.8% agarose gel. The sizes of the molecular weight standards are shown on the right (lane 6). 
Restriction enzymes used for the reactions correspond to pDAFI3 single digest with Xbal (lane 2), pDAFI3 
single digest with ClaI (lane 3), pDAFI3 double digest with Xbal and ClaI (lane 4), and pUC75 double 
digest with Xbal and ClaI (lane 5). Control of wild-type TMEV pDAFI3 cDNA plasmid in lane 1. 1kB plus 






















Figure 6: Linearization of pDAFI3 plasmid. In-vitro transcription was performed to purify the TMEV 
linear RNA product digested with Xbal. Linearized pDAFI3 product was visualized by electrophoresis 
using a 0.7% agarose gel. The sizes of the molecular weight standards are shown on the left (lane 1). Linear 
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Figure 7: Cytopathic effect of TMEV-infected BHK-21 cells. Changes to morphology of the BHK-21 
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